invest summari beat posit outlook ahead
import pipelin data reiter ow rate price target
share think respect earn growth driven innov
medicin pipelin advanc return capit sharehold
industri averag underappreci therefor multipl
expans upward earn revis drive share higher
 takeaway support posit thesi rev reflect op
growth rev reflect oper growth return
directli sharehold share repurchas dividend
anticip repurchas share surpris us
guidanc came factset consensu guidanc includ
full year revenu expens contribut consum healthcar
unfavor fx impact rev adjust dilut ep
guidanc exclud impact gain loss equiti invest
favor impact ep midpoint guidanc
rang given impli essenti flat oper perform vs
absorb anticip revenu headwind due product
recent lost expect soon lose market exclus
expect year import clinic data readout across
pipelin expect report pivot top-lin result tanezumab clbp
well addit data oa anticip report pivot result
rivipansel vaso-occlus crisi sickl cell diseas well
result first phase trial abrocitinib
moderate-to-sever ad data two nonalcohol steatohepat
candid psoriasi data two tyrosin
kinas inhibitor candid
dual inhibitor immun respons data respiratori syncyti
viru infect pentaval meningococc
vaccin candid also expect provid earli clinic data mini-
dystrophin gene therapi candid boy dmd
gene therapi program hemophilia
report adjust dilut ep factset
consensu higher estim present ep
guidanc midpoint factset consensu
adjust financi model report outlook
decreas ep estim
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk invest thesi price target
product repres signific portion sale could face gener
competit current portfolio product may face competit cannib
pipelin introduct new competit could diminish price
power exist drug record direct product and/or allianc revenu
billion nine biopharmaceut product prevnar lyrica
ibranc eliqui enbrel lipitor xeljanz viagra sutent account total
revenu product pfizer major product subject
problem loss patent protect applic chang prescript growth rate
affect doctor patient confid pressur exist competit product chang
label access pressur new more-effect treatment introduc
advers impact revenu could signific
pipelin delay failur and/or higher-than-forecast competit gener
may continu face access challeng biosimilar product market
biosimilar product may receiv access pariti innov product remain
disadvantag posit exampl inflectra/remsima experienc access challeng
risk relat strateg acquisit success recent acquisit
hospira anacor mediv astrazeneca small molecul anti-infect busi
depend larg part compani abil realiz anticip benefit combin
busi exist segment exampl may fail achiev
anticip cost save acquisit hospira cost save within
expect time frame accret impact anticip acquisit hospira
anacor mediv may realiz may delay also may fail gener
revenu growth acquir busi expect time enter
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casesal ibranc eliqui xeljanzand key drug exceed expectationspipelin advanc exceed expectationsstrateg accret scenario casesal ibranc eliqui xeljanzand key drug line expectationspipelin advanc line expectationsno scenario casesal ibranc eliqui xeljanzand key drug expectationspipelin advanc expectationsno scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot growth key brand ibranc ex-u eliqui xeljanz prevenar emerg favor foreign exchang impact lower sip sale carri higher cost produc gross lower invest across sever ih product benefit cost-reduction/product initi oper non oper pre-tax tax net dilut share adjust dilut cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom biosimilar trastuzumab bsufa date februari recoveri suppli shortag per fda biosimilar bevacizumab bsufa avelumab inlyta axitinib file base phase javelin renal data renal cell carcinoma mini-dystrophin gene therapi phase earli data duchenn muscular dystrophi phase long-term efficaci safeti top-line readout oa top-line readout clbp spring asept process map facilitygroundbreak portag loss exclusivityjuli meglumin form mg capsul pdufa data vaso-occlus crisi hospit subject sickl cell biosimilar rituximab bsufa avelumabiniti phase trial head neck squamou cell talazoparib comboiniti phase trial enzalutamid comboiniti phase trial adalimumab biosimilar bsufa palbociclib ibranc present preliminari phase data jade moder sever ad top-line healthcar businessclos transact biosimilar rituximab safeti efficaci result phase data open label studi data hemophilia avelumab best support care phase javelin bladder data bladder mainten javelin lung data nsclc javelin gastric data gastric mainten therapeuticsent phase partial agonist parkinson diseas symptom novemb free acid form mg capsul pdufa datedecemb vaccinephas data respiratori syncyti viru end inject businessexpect suppli constraint issu significantli data rheumatoid interim analysi prophylact vaccin phase data invas group streptococcu agonist phase data rheumatoid data rheumatoid combo nab-paclitaxel phase data pancreat ductal updat patent sunitinib ema decis adjuv treatment high risk isavuconazol addit launchessourc cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom multival pneumococc conjug vaccin estimate primari complet date phase trialapril anti data atop enzalutamid leuprolidephas embark data nonmetastat month stay expiresnovemb patent palbociclib phase patina data breast coagul factor ix data hemophilia readout cancer tfpi mab phase data hemophilia data crohn data ankylos talazoparib avelumabphas javelin parp medley data local advanc metastat solid talazoparib phase data metastat data activ non-segment prophylact vaccin phase clover data clostridium difficil therapeut vaccin phase data vaccine-bas immunotherapi regimen prostat data moder sever ulcer palbociclib phase penelop data high-risk earli breast palbociclib phase palla data intermediate-risk earli breast oral inhibitor phase trial complet alopecia asept process map facilitycomplet construct portag combo w/ soc chemoradi crt phase javelin head neck data head neck talazoparib avelumabphas javelin brca/atm data metastat solid tumor brca atm eu patent eu patent expirationend co-promot talazoparib w/ novel hormon therapi nht phase data metastat castration-resist talazoparib phase javelin ovarian parp data previous untreat advanc ovarian patent patent palbociclib us/major eu/japan patent palbociclib major eu patent adalimumab biosimilar licens period begin per agreement asept process map facilitybegin product portag patent eu/japan patent patent eu patent patent eu/japan patent eu patent enzalutamid us patent patent eu patent patent patent patent patent avelumab major eu/japan patent avelumab us patent expirationsourc cantor fitzgerald research compani report exhibit cantor estim vs manag guidanc
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
pfizer inc engag discoveri develop manufactur healthcar product
compani nyse overweight
price close jan
